Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

BioCurcumin works in patients with painful rheumatoid arthritis

Aug 07, 2013

     In this recent study run by researchers at Baylor Medical College 45 patients with rheumatoid arthritis were randomly split into 3 groups. One group was given the anti-inflammatory prescription drug diclofenac sodium (one brand name is Voltaren®) 50 mg twice daily, the second group of patients were supplemented with BioCurcumin at a dosage of 500 mg twice daily. The third group was placed on a combination of the two. Unlike osteoarthritis which typically affects one joint Rheumatoid arthritis can affect dozens of joints causing deformity, pain and loss of function.

The results of the study were judged using the clinically validated Disease Activity Score (DAS) 28 which assesses the health of 28 different joints and also with the American College of Rheumatology (ACR) criteria and scores for pain and swelling in joints. Patients in all 3 groups improved. The BioCurcumin group showed the greatest improvement, and the scores were significantly better than the patients in the drug group. BioCurcumin was better for relieving joint pain, joint swelling, joint tenderness, joint inflammation, and for improving stiffness and range of motion. BioCurcumin reduced joint pain without any toxicity by 45% where the drug reduced it by 42%. Using both interventions concurrently did not show any additional benefit with regards to disease scores versus either agent alone. The VAS Score is the visual analog score. The VAS assessment is the patients own opinion of the quality of a treatment. In the VAS assessment patients state that BioCurcumin improved their disease by 60% and the drug improved it by 50%; again the herb that is proven to be safe in many human clinical trials outperformed a commonly prescribed and dangerous drug.

At the start of the study the total number of diseased joints per patient in the BioCurcumin group dropped from 19 on average to 3 on average. In the drug group it dropped from 18 diseased joints on average to 6 on average. The total number of swollen joints in the herb group dropped from 12 per patient to zero but in the drug group it dropped from 17 to 2. The patients on BioCurcumin had an easier time grooming, dressing, arising out of a chair and walking than the group on diclofenac. Curcumin was found to be safe with no adverse effects in this study. In the drug it should be noted that 14% of the patients withdrew because of adverse effects. The study is published in the March 9, 2012 issue of the journal Phytotherapy Research.